<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01180894</url>
  </required_header>
  <id_info>
    <org_study_id>10-0705</org_study_id>
    <nct_id>NCT01180894</nct_id>
  </id_info>
  <brief_title>IV Iron for the Anemia of Traumatic Critical Illness</brief_title>
  <acronym>IATCI</acronym>
  <official_title>A Multicenter, Randomized, Double-blind Comparison of Intravenous Iron Supplementation to Placebo for the Treatment of Anemia of Traumatic Critical Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denver Health and Hospital Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Trauma Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Denver Health and Hospital Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to determine whether intravenous iron supplementation
      of anemic, critically ill trauma patients improves anemia and reduces the need for a red
      blood cell transfusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nearly all trauma patients admitted to an intensive care unit (ICU) are anemic (low red blood
      cell counts). Anemia is an independent risk factor for poor outcomes, including infection,
      impaired wound healing, and death. Current therapies for ICU anemia are unsatisfactory: Red
      blood cell (RBC) transfusion is associated with an increased risk of immune suppression,
      infection, and organ failure. Furthermore, use of both hemoglobin replacement products and
      erythropoietin are limited by expense as well as unfavorable side effect profiles.

      One principal cause of anemia in trauma ICU patients involves disturbances in iron
      metabolism. Iron is necessary to make RBCs, and a lack of iron delivered to the bone marrow
      results in anemia. Trauma causes diversion of iron from the bone marrow into storage, where
      it cannot participate in the generation of RBCs. This diversion of iron is caused by
      inflammatory proteins released as a result of tissue injury.

      Previous work by the principal investigator among ICU patients suggested a benefit to oral
      iron supplementation administered in dosages similar to those used in a standard
      multivitamin. However, many patients were not able to tolerate oral medications, and this
      study was not specific to trauma patients. Additional research has suggested that intravenous
      iron supplementation is effective in treating anemic patients with other inflammatory
      conditions, such as cancer and inflammatory bowel disease. However, the benefit of
      intravenous iron supplementation has never been tested among anemic ICU patients, including
      trauma patients.

      The current clinical trial will evaluate the risk/benefit profile of intravenous iron
      supplementation among anemic trauma ICU patients. The study will take place over several
      academic trauma centers with a long history of participation in translational research.

      Anemia remains a devastating complication of trauma. Current treatment options are limited.
      Intravenous iron supplementation represents a targeted, cost-effective solution to this
      pervasive problem, the efficacy of which remains undefined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RBC Transfusion</measure>
    <time_frame>42 Days</time_frame>
    <description>The number of participants who underwent RBC transfusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Iron-deficient Erythropoeisis (IDE)</measure>
    <time_frame>14 Days</time_frame>
    <description>An elevated eZPP is diagnostic of Iron-deficient erythropoiesis (IDE) and reflects the bone marrow iron supply regardless of total body iron.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection</measure>
    <time_frame>28 Days</time_frame>
    <description>The number of participants with at least one infection.
Specific infections analyzed included VAP (Ventilator-Associated Pneumonia), bacteremia, and urinary tract infection (UTI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Who Died</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Trauma</condition>
  <condition>ICU Anemia</condition>
  <arm_group>
    <arm_group_label>Iron sucrose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg IV TIW</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pacebo - Normal Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron sucrose</intervention_name>
    <description>100 mg IV TIW</description>
    <arm_group_label>Iron sucrose</arm_group_label>
    <other_name>Fe sucrose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ICU admission for trauma

          -  Adults (age ≥ 18 years)

          -  Anemia (hemoglobin &lt; 12 g/dL)

          -  ≤ 72 hours from ICU admission

          -  Expected ICU length of stay ≥ 7 days

        Exclusion Criteria:

          -  Active hemorrhage requiring RBC transfusion

          -  Iron overload (serum ferritin concentration ≥ 1,000 ng/mL) or any condition associated
             with iron overload (e.g., hemochromatosis, aceruloplasminemia

          -  Chronic inflammatory conditions (e.g., systemic lupus erythematosis, rheumatoid
             arthritis, ankylosing spondilitis)

          -  Pre-existing hematologic disorders (e.g., thalassemia, sickle cell disease,
             hemophilia, von Willibrand's disease, myeloproliferative disease)

          -  Macrocytic anemia (mean corpuscular volume ≥ 100 fL)

          -  Current use of immunosuppressive agents including corticosteroids (e.g.,
             dexamethasone, hydrocortisone, methylprednisolone, prednisone, exclusive of inhaled
             corticosteroids), calcinurin inhibitors (e.g., cyclosporine, tacrolimus),
             antimetabolites (e.g., azathioprine), or biologics (e.g., OKT3, thymoglobulin)

          -  Use of recombinant human erythropoietin formulation within the prev 30 days

          -  Pregnancy or lactation

          -  Prohibition of RBC transfusion

          -  Stay of ≥ 48 hours duration in the ICU of a transferring hospital

          -  History of intolerance or hypersensitivity to either enteral or intravenous iron

          -  Moribund state in which death is imminent

          -  Enrollment in any other clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fredric M Pieracci, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Health Medical Center, University of Colorado Health Science Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health Systems</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NewYork Presbyterian Medical Center/Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center/University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nationaltraumainstitute.org/</url>
    <description>National Trauma Institute</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2010</study_first_submitted>
  <study_first_submitted_qc>August 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2010</study_first_posted>
  <results_first_submitted>September 16, 2015</results_first_submitted>
  <results_first_submitted_qc>November 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2017</results_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Denver Health and Hospital Authority</investigator_affiliation>
    <investigator_full_name>Fredric Pieracci</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Trauma</keyword>
  <keyword>Anemia</keyword>
  <keyword>Iron</keyword>
  <keyword>Erythropoeisis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Iron Sucrose</title>
          <description>100 mg IV TIW
Iron sucrose: 100 mg IV TIW</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (100 mg normal saline)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Iron Sucrose</title>
          <description>100 mg IV TIW
Iron sucrose: 100 mg IV TIW</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo
100 mg Normal saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.6" lower_limit="18" upper_limit="83"/>
                    <measurement group_id="B2" value="40.4" lower_limit="18" upper_limit="87"/>
                    <measurement group_id="B3" value="41.0" lower_limit="18" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>RBC Transfusion</title>
        <description>The number of participants who underwent RBC transfusion.</description>
        <time_frame>42 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Sucrose</title>
            <description>100 mg IV TIW
Iron sucrose: 100 mg IV TIW</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Pacebo - Normal Saline
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>RBC Transfusion</title>
          <description>The number of participants who underwent RBC transfusion.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Iron-deficient Erythropoeisis (IDE)</title>
        <description>An elevated eZPP is diagnostic of Iron-deficient erythropoiesis (IDE) and reflects the bone marrow iron supply regardless of total body iron.</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Sucrose</title>
            <description>100 mg IV TIW
Iron sucrose: 100 mg IV TIW</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
100 mg Normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Iron-deficient Erythropoeisis (IDE)</title>
          <description>An elevated eZPP is diagnostic of Iron-deficient erythropoiesis (IDE) and reflects the bone marrow iron supply regardless of total body iron.</description>
          <units>micro mol: mol heme</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118" lower_limit="64" upper_limit="344"/>
                    <measurement group_id="O2" value="118" lower_limit="78" upper_limit="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infection</title>
        <description>The number of participants with at least one infection.
Specific infections analyzed included VAP (Ventilator-Associated Pneumonia), bacteremia, and urinary tract infection (UTI).</description>
        <time_frame>28 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Sucrose</title>
            <description>100 mg IV TIW
Iron sucrose: 100 mg IV TIW</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (100 mg normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>Infection</title>
          <description>The number of participants with at least one infection.
Specific infections analyzed included VAP (Ventilator-Associated Pneumonia), bacteremia, and urinary tract infection (UTI).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Who Died</title>
        <time_frame>28 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Iron Sucrose</title>
            <description>100 mg IV TIW
Iron sucrose: 100 mg IV TIW</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (100 mg normal saline)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Died</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Iron Sucrose</title>
          <description>100 mg IV TIW
Iron sucrose: 100 mg IV TIW</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo
100 mg Normal saline</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Mortality</sub_title>
                <description>In hospital mortality</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="75"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Fredric Pieracci</name_or_title>
      <organization>Denver Health Hospital</organization>
      <phone>303-436-4029</phone>
      <email>fredric.pieracci@dhha.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

